Unjoni Ewropea - Ingliż - EMA (European Medicines Agency)

roche registration ltd. - daclizumab - graft rejection; kidney transplantation - immunosuppressants - zenapax is indicated for the prophylaxis of acute organ rejection in de novo allogenic renal transplantation and is to be used concomitantly with an immunosuppressive regimen, including cyclosporine and corticosteroids in patients who are not highly immunised.

Armenja - Ingliż - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

roche diagnostics gmbh - bevacizumab - concentrate for solution for infusion - 25mg/ml

Armenja - Ingliż - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

roche diagnostics gmbh - bevacizumab - concentrate for solution for infusion - 25mg/ml

Iżrael - Ingliż - Ministry of Health

novartis israel ltd - omalizumab - powder and solvent for solution for injection - omalizumab 150 mg/dose - omalizumab - omalizumab - allergic asthma xolair is indicated for patients 6 to 12 years of age with severe persistent asthma and for patients 12 years of age and older with moderate to severe persistent asthma, who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. xolair has been shown to decrease the incidence of asthma exacerbations in these patients. limitations of use: xolair is not indicated for the relief of acute bronchospasm or status asthmaticus. xolair is not indicated for the treatment of other allergic conditions.chronic rhinosinusitis with nasal polyps (crswnp) xolair is indicated as an add-on therapy with intranasal corticosteroids (inc) for the treatment of adults (18 years and above) with severe crswnp for whom therapy with inc does not provide adequate disease control.chronic spontaneous urticaria (csu) xolair is indicated as add-on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent (12 years and above) patients with inadequate response to h1 antihistamine treatment.

Singapor - Ingliż - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - omalizumab - injection, powder, lyophilized, for solution - 150mg - omalizumab 150mg

Singapor - Ingliż - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - omalizumab - injection, powder, lyophilized, for solution - 75mg - omalizumab 75mg

Singapor - Ingliż - HSA (Health Sciences Authority)

roche singapore pte. ltd. - bevacizumab - infusion, solution concentrate - 25mg - bevacizumab 25mg

Singapor - Ingliż - HSA (Health Sciences Authority)

roche singapore pte. ltd. - bevacizumab - infusion, solution concentrate - 400mg - bevacizumab 400mg

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - tocilizumab -

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - bevacizumab -